Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemolizumab dose-ranging in moderate-to-severe atopic dermatitis with severe pruritus
2016-005025-37Phase 2Completed
- Sponsor
- Galderma
- Start
- May 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing Nemolizumab + topical corticosteroids with Placebo + topical corticosteroids (2 arms). Primary endpoint: Percentage change in EASI. Started May 2017; status: completed.
02
Drugs
nemolizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2016-005025-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-005025-37.